Janssen R And D patents expiration
1. Intelence patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7887845 | JANSSEN R AND D | Antiviral compositions |
Mar, 2019
(5 years ago) | |
|
US7887845 (Pediatric) | JANSSEN R AND D | Antiviral compositions |
Sep, 2019
(4 years ago) | |
| US8003789 | JANSSEN R AND D | HIV replication inhibiting pyrimidines |
Nov, 2019
(4 years ago) | |
| US6878717 | JANSSEN R AND D | HIV replication inhibiting pyrimidines |
Nov, 2019
(4 years ago) | |
|
US8003789 (Pediatric) | JANSSEN R AND D | HIV replication inhibiting pyrimidines |
May, 2020
(4 years ago) | |
|
US6878717 (Pediatric) | JANSSEN R AND D | HIV replication inhibiting pyrimidines |
May, 2020
(3 years ago) | |
| US7037917 | JANSSEN R AND D | HIV replication inhibiting pyrimidines |
Dec, 2020
(3 years ago) | |
|
US7037917 (Pediatric) | JANSSEN R AND D | HIV replication inhibiting pyrimidines |
Jun, 2021
(2 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Pediatric Exclusivity(PED) | Jan 16, 2022 |
| New Patient Population(NPP) | Mar 26, 2015 |
| New Chemical Entity Exclusivity(NCE) | Jan 18, 2013 |
Drugs and Companies using ETRAVIRINE ingredient
NCE-1 date: 16 January, 2021
Market Authorisation Date: 26 March, 2012
Treatment: Combo w/ other antiretrovirals for tx of hiv-1 in antiretroviral tx-experienced pt 6 years up, who have evidence of viral replication and hiv-1 strains resistant to non-nucleoside reverse transcriptas...
Dosage: TABLET;ORAL
More Information on Dosage
INTELENCE family patents
